Safe and Efficient Gene Therapy for Pyruvate Kinase Deficiency

Area of Science:

• Hematology
• Metabolic disorders
• Gene therapy

Background:

• Pyruvate kinase deficiency (PKD) is a genetic disorder affecting red blood cells, leading to hemolytic anemia.
• The condition is caused by mutations in the PKLR gene and can be severe, especially in newborns.
• Gene therapy presents a promising avenue for treating inherited metabolic diseases like PKD.

Purpose of the Study:

• To develop and evaluate a preclinical gene therapy for pyruvate kinase deficiency (PKD).
• To assess the efficacy of a lentiviral vector carrying the PKLR gene in correcting the disease phenotype in a mouse model.

Main Methods:

• Hematopoietic stem cells (HSCs) from PKD mice were genetically modified using a lentiviral vector containing the human phosphoglycerate kinase (hPGK) promoter and PKLR cDNA.
• These corrected HSCs were transplanted into myeloablated PKD mice.
• Hematological parameters, organ pathology, and metabolic profiles of red blood cells (RBCs) and leukocytes were analyzed.

Main Results:

• Ectopic expression of pyruvate kinase (RPK) normalized the erythroid compartment and corrected the hematological phenotype.
• Organ pathology associated with PKD was reverted.
• Metabolomic studies confirmed functional correction of the glycolytic pathway in RBCs, with no adverse metabolic effects in leukocytes.
• Genotoxicity analysis showed no evidence of adverse events from lentiviral vector integration.

Conclusions:

• The hPGK-coRPK lentiviral vector demonstrates significant therapeutic potential for pyruvate kinase deficiency.
• This study provides strong preclinical evidence supporting gene therapy for PKD and other erythroid metabolic genetic disorders.